The Tysabri Test
Biogen Idec and Elan's multiple sclerosis therapy Tysabri is testing a key tenet of personalized medicine: that payors will accept the argument that smaller markets require higher prices.
Biogen Idec and Elan's multiple sclerosis therapy Tysabri is testing a key tenet of personalized medicine: that payors will accept the argument that smaller markets require higher prices.